Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
复制标题
DOI：
10.1186/s12885-020-07214-4
复制
发表时间：
2020-08-05
期刊：
影响因子：
3.8
通讯作者：
Ahn, Myung-Ju
中科院分区：
文献类型：
--
作者：
Kim, Hyera;Kwon, Minsuk;Ahn, Myung-Ju
背景抗PD 1抑制剂已被批准用于治疗复发性或转移性头颈癌（HNC），作为全球III期试验的结果。然而，免疫检查点抑制剂在不符合临床试验条件或具有各种医疗条件的患者中的临床结果尚未完全阐明。MethodsWe回顾性分析了2016年6月至2019年6月期间接受pembrolizumab或nivolumab治疗的46例复发或转移性HNC患者。口腔、下咽、喉、鼻腔或鼻窦，11例为鼻咽癌（NPC）。中位无进展生存期（PFS）和总生存期（OS）HNSCC分别为3.7个月和6.8个月，NPC分别为4.3个月和11.8个月。所有患者的客观缓解率（ORR）为21%。在30例HNSCC患者中，5例患者获得完全缓解，2例获得部分缓解（ORR 23%）; 8例NPC患者中有1例获得部分缓解（13%）。既往接受过放疗的患者的OS优于未接受过放疗的患者（中位OS，7.6个月vs. 2.3个月，p=0.006）。接受pembrolizumab治疗的患者的OS长于接受nivolumab治疗的患者（中位OS，11.8个月对6.8个月，p=0.017）。
BackgroundAnti-PD1 inhibitors have been approved for the treatment of recurrent or metastatic head and neck cancer (HNC), as a result of Global Phase III trials. However, the clinical outcomes of immune checkpoint inhibitors in patients who are not eligible for clinical trials or have various medical conditions have not been fully elucidated.MethodsWe retrospectively reviewed 46 patients with recurrent or metastatic HNC who received pembrolizumab or nivolumab between June 2016 and June 2019.ResultsThirty-five patients had head and neck squamous cell carcinoma (HNSCC) affecting the oropharynx, oral cavity, hypopharynx, larynx, nasal cavity, or paranasal sinuses, and eleven patients had nasopharyngeal cancer (NPC). The median progression-free survival (PFS) and overall survival (OS) were 3.7months and 6.8months, respectively, for patients with HNSCC, and 4.3months and 11.8months, respectively, for patients with NPC. The objective response rate (ORR) in all patients was 21%. Of 30 patients with HNSCC, 5 patients achieved complete response and 2 achieved partial response (ORR 23%); 1 of 8 NPC patients achieved partial response (13%). Patients who previously underwent radiotherapy had better OS than those who did not (median OS, 7.6months vs. 2.3months, p=0.006). OS was longer in patients treated with pembrolizumab than in those treated with nivolumab (median OS, 11.8months vs. 6.8months, p=0.017).ConclusionConsistent with previous reports, immune checkpoint inhibitors showed promising efficacy in patients with previously treated recurrent or metastatic HNC in a real-world setting.